Related references
Note: Only part of the references are listed.Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation
Susan D. Mathias et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) questionnaire
David Cella et al.
SUPPORTIVE CARE IN CANCER (2006)
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis
CA Marra et al.
SOCIAL SCIENCE & MEDICINE (2005)
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis
C Moretti et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
The development and psychometric evaluation of the Motivation and Energy Inventory (MEI)
SE Fehnel et al.
QUALITY OF LIFE RESEARCH (2004)
Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro
M Chang et al.
BLOOD (2003)
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales
D Cella et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Fatigue in cancer patients compared with fatigue in the general United States population
D Cella et al.
CANCER (2002)
Share Paper
